Project: The world’s first personalised liquid biopsy test for disease monitoring in paediatric cancers
| Acronym | MonitoRD (Reference Number: 115579) |
| Duration | 01/09/2021 - 01/09/2023 |
| Project Topic | MonitoRD will deliver the first personalised liquid biopsy test for disease monitoring in paediatric cancers. Tumour-specific genetic markers (breakpoints) identified by a proprietary targeted locus amplification technology will be used to develop a personalised Crystal Digital PCR (dPCR) kit to quantify circulating tumour DNA with unprecedented sensitivity. After the project, the NBCheck test for disease monitoring in neuroblastoma patients will be ready for final CE-mark validation studies. |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 15 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | Cergentis B.V. | Coordinator | Netherlands |
| 2 | Institut Curie | Partner | France |
| 3 | Princess Máxima Center | Partner | Netherlands |
| 4 | Stilla Technologies | Partner | France |